* participation in another clinical study (with use of another investigational medical product) within 3 months prior to study treatment start * unwillingness or inability to comply with study procedures * patients with serious basic diseases that affect survival, including blood diseases, cachexia, active bleeding, severe malnutrition, etc. * clinically active malignant disease * subjects who are receiving ecmo and crrt currently * history of known pulmonary embolism or known secondary anti-phospholipid syndrome * known or suspected hypersensitivity to any components used to culture the admscs, e.g. bsa and sulfur containing products (e.g., dmso) * known or suspected allergic to diphenhydramine. * major trauma or surgery within 14 days of study treatment start * mental condition rendering the subject (or the subject's legally acceptable representative\[s\]) unable to understand the nature, scope and possible consequences of the study * alcohol, drug, or medication abuse within one year prior to study treatment start * any condition that, in the investigator's opinion, is likely to interfere with evaluation of the admsc therapy or satisfactory conduct of the study * irreversible severe end organ failure, such as heart failure/attack, stroke, liver and renal failure due to other disease conditions * patients or family history with hypercoagulable status, such as protein c/protein s deficiency, factor v leiden, prothrombin gene mutation, dysfibrinogenemia, etc. * history of long-term use of immunosuppressive agents * organ transplants in the past 6 months * pregnant, breastfeeding, or desire to become pregnant or unwilling to practice birth control during participation in the study duration, unless surgically sterilized or postmenopausal during the study. * patients with previous pulmonary obstructive pneumonia, severe pulmonary interstitial fibrosis, alveolar proteinosis, allergic alveolitis, and other known viral pneumonia or bacterial pneumonia before covid-19 infection. the pulmonary imaging revealed the interstitial damage of lungs before the covid-19 confirmed. * qt interval shows greater than 450 ms in males and 470 ms in females in the medical histories or during screen ekg test. * subjects are not medically unstable at time of infusion including but not limiting unstable hypertension, pulse, oximetry, etc.

* participation in another clinical study (with use of another investigational medical product) within 3 months prior to study treatment start * unwillingness or inability to comply with study procedures * patients with serious basic diseases that affect survival, including blood diseases, cachexia, active bleeding, severe malnutrition, etc. * clinically active malignant disease * subjects who are receiving ecmo and crrt currently * history of known pulmonary embolism or known secondary anti-phospholipid syndrome * known or suspected hypersensitivity to any components used to culture the admscs, e.g. bsa and sulfur containing products (e.g., dmso) * known or suspected allergic to diphenhydramine. * major trauma or surgery within 14 days of study treatment start * mental condition rendering the subject (or the subject's legally acceptable representative\[s\]) unable to understand the nature, scope and possible consequences of the study * alcohol, drug, or medication abuse within one year prior to study treatment start * any condition that, in the investigator's opinion, is likely to interfere with evaluation of the admsc therapy or satisfactory conduct of the study * irreversible severe end organ failure, such as heart failure/attack, stroke, liver and renal failure due to other disease conditions * patients or family history with hypercoagulable status, such as protein c/protein s deficiency, factor v leiden, prothrombin gene mutation, dysfibrinogenemia, etc. * history of long-term use of immunosuppressive agents * organ transplants in the past 6 months * pregnant, breastfeeding, or desire to become pregnant or unwilling to practice birth control during participation in the study duration, unless surgically sterilized or postmenopausal during the study. * patients with previous pulmonary obstructive pneumonia, severe pulmonary interstitial fibrosis, alveolar proteinosis, allergic alveolitis, and other known viral pneumonia or bacterial pneumonia before covid-19 infection. the pulmonary imaging revealed the interstitial damage of lungs before the covid-19 confirmed. * qt interval shows greater than 450 ms in males and 470 ms in females in the medical histories or during screen ekg test. * subjects are not medically unstable at time of infusion including but not limiting unstable hypertension, pulse, oximetry, etc.

- participation in another clinical study (with use of another investigational medical product) within 3 months prior to study treatment start - unwillingness or inability to comply with study procedures - patients with serious basic diseases that affect survival, including blood diseases, cachexia, active bleeding, severe malnutrition, etc. - clinically active malignant disease - subjects who are receiving ecmo and crrt currently - history of known pulmonary embolism or known secondary anti-phospholipid syndrome - known or suspected hypersensitivity to any components used to culture the admscs, e.g. bsa and sulfur containing products (e.g., dmso) - known or suspected allergic to diphenhydramine. - major trauma or surgery within 14 days of study treatment start - mental condition rendering the subject (or the subject's legally acceptable representative[s]) unable to understand the nature, scope and possible consequences of the study - alcohol, drug, or medication abuse within one year prior to study treatment start - any condition that, in the investigator's opinion, is likely to interfere with evaluation of the admsc therapy or satisfactory conduct of the study - irreversible severe end organ failure, such as heart failure/attack, stroke, liver and renal failure due to other disease conditions - patients or family history with hypercoagulable status, such as protein c/protein s deficiency, factor v leiden, prothrombin gene mutation, dysfibrinogenemia, etc. - history of long-term use of immunosuppressive agents - organ transplants in the past 6 months - pregnant, breastfeeding, or desire to become pregnant or unwilling to practice birth control during participation in the study duration, unless surgically sterilized or postmenopausal during the study. - patients with previous pulmonary obstructive pneumonia, severe pulmonary interstitial fibrosis, alveolar proteinosis, allergic alveolitis, and other known viral pneumonia or bacterial pneumonia before covid-19 infection. the pulmonary imaging revealed the interstitial damage of lungs before the covid-19 confirmed. - qt interval shows greater than 450 ms in males and 470 ms in females in the medical histories or during screen ekg test. - subjects are not medically unstable at time of infusion including but not limiting unstable hypertension, pulse, oximetry, etc.

- participation in another clinical study (with use of another investigational medical product) within 3 months prior to study treatment start - unwillingness or inability to comply with study procedures - patients with serious basic diseases that affect survival, including blood diseases, cachexia, active bleeding, severe malnutrition, etc. - clinically active malignant disease - subjects who are receiving ecmo and crrt currently - history of known pulmonary embolism or known secondary anti-phospholipid syndrome - known or suspected hypersensitivity to any components used to culture the admscs, e.g. bsa and sulfur containing products (e.g., dmso) - known or suspected allergic to diphenhydramine. - major trauma or surgery within 14 days of study treatment start - mental condition rendering the subject (or the subject's legally acceptable representative[s]) unable to understand the nature, scope and possible consequences of the study - alcohol, drug, or medication abuse within one year prior to study treatment start - any condition that, in the investigator's opinion, is likely to interfere with evaluation of the admsc therapy or satisfactory conduct of the study - irreversible severe end organ failure, such as heart failure/attack, stroke, liver and renal failure due to other disease conditions - patients or family history with hypercoagulable status, such as protein c/protein s deficiency, factor v leiden, prothrombin gene mutation, dysfibrinogenemia, etc. - history of long-term use of immunosuppressive agents - organ transplants in the past 6 months - pregnant, breastfeeding, or desire to become pregnant or unwilling to practice birth control during participation in the study duration, unless surgically sterilized or postmenopausal during the study. - patients with previous pulmonary obstructive pneumonia, severe pulmonary interstitial fibrosis, alveolar proteinosis, allergic alveolitis, and other known viral pneumonia or bacterial pneumonia before covid-19 infection. the pulmonary imaging revealed the interstitial damage of lungs before the covid-19 confirmed. - qt interval shows greater than 450 ms in males and 470 ms in females in the medical histories or during screen ekg test. - subjects are not medically unstable at time of infusion including but not limiting unstable hypertension, pulse, oximetry, etc.